anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is renowned for its formidable and lethal nature, earning it a notorious reputation among malignant tumors. Due to its challenging early diagnosis, high malignancy, and resistance to chemotherapy drugs, the treatment of pancreatic cancer has long been exceedingly difficult in the realm of oncology. γ-Glutamyl cyclotransferase (GGCT), a vital enzyme in glutathione metabolism, has been implicated in the proliferation and progression of several tumor types, while the biological function of GGCT in pancreatic ductal adenocarcinoma remains unknown.
METHODS: The expression profile of GGCT was validated through western blotting, immunohistochemistry, and RT-qPCR in both pancreatic cancer tissue samples and cell lines. Functional enrichment analyses including GSVA, ssGSEA, GO, and KEGG were conducted to explore the biological role of GGCT. Additionally, CCK8, Edu, colony formation, migration, and invasion assays were employed to evaluate the impact of GGCT on the proliferation and migration abilities of pancreatic cancer cells. Furthermore, the LASSO machine learning algorithm was utilized to develop a prognostic model associated with GGCT.
RESULTS: Our study revealed heightened expression of GGCT in pancreatic cancer tissues and cells, suggesting an association with poorer patient prognosis. Additionally, we explored the immunomodulatory effects of GGCT in both pan-cancer and pancreatic cancer contexts, found that GGCT may be associated with immunosuppressive regulation in various types of tumors. Specifically, in patients with high expression of GGCT in pancreatic cancer, there is a reduction in the infiltration of various immune cells, leading to poorer responsiveness to immunotherapy and worse survival rates. In vivo and in vitro assays indicate that downregulation of GGCT markedly suppresses the proliferation and metastasis of pancreatic cancer cells. Moreover, this inhibitory effect appears to be linked to the regulation of GGCT on c-Myc. A prognostic model was constructed based on genes derived from GGCT, demonstrating robust predictive ability for favorable survival prognosis and response to immunotherapy.
Paraplatin ® (carboplatin) Injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available. 

Bone marrow suppression is dose related and may be severe, resulting in infection and/or bleeding. Anemia may be cumulative and may require transfusion support. Vomiting is another frequent drug related side effect.

Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of Paraplatin ® administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.
The control strategy of rehabilitation robots should not only adapt to patients with different levels of motor function but also encourage patients to participate voluntarily in rehabilitation training. However, existing control strategies usually consider only one of these aspects. This study proposes a voluntary and adaptive control strategy that solves both questions. Firstly, the controller switched to the corresponding working modes (including challenge, free, assistant, and robot-dominant modes) based on the trajectory tracking error of human-robot cooperative movement. To encourage patient participation, a musculoskeletal model was used to estimate the patient's active torque. The robot's output torque was designed as the product of the active torque and a coefficient, with the coefficient adaptively changing according to the working mode. Experiments were conducted on two healthy subjects and four hemiplegic patients using an ankle rehabilitation robot. The results showed that this controller not only provided adaptive the robot's output torque based on the movement performance of patients but also encouraged patients to complete movement tasks themselves. Therefore, the control strategy has high application value in the field of rehabilitation.
FIELD: medicine. ^ SUBSTANCE: pharmaceutical composition contains a granulated component including multiple hardened melt granules of sugar alcohol containing included salt of nonsteroidal anti-inflammatory drug (NSAID salt) and paracetamol. The mass ratio of NSAID salt to paracetamol is 1:5 to 3:1. The pharmaceutical composition is used for pain and/or inflammation and/or fever management in coughing, cold, influenza, migraine, headache, rheumatic pain, articular pain, muscular pain and/or neuralgia. ^ EFFECT: according to the invention, the pharmaceutical composition contains minimum of tableting excipients, has improved fluidity and does not tend to adhere to stamps of a tableting machine. ^ 38 cl, 3 dwg, 4 tbl, 21 ex
The invention discloses a drug information recommendation method and system based on artificial intelligence, comprising the following steps: historical medication data of a target user is first obtained, the data including at least information of all medications used by the target user during a specific period of time. These historical medication data are then entered into a pre-trained drug function inference model to determine target drug functions that are associated with the drugs used by the user over a specified period of time. The target drug is further determined based on the determined target drug function. And finally, generating medicine recommendation information according to the target medicine, and sending the recommendation information to the target user. By the design, accuracy and efficiency of medicine recommendation are improved, and medicine effect and health condition of a patient can be improved. Meanwhile, the historical medication data of the user is analyzed, so that the medication requirement and habit of the user can be better understood, more personalized medication recommendation is realized, and the satisfaction degree of the user and the medical service quality are improved.
The investigators are proposing a prospective, longitudinal, cross-sectional, and patient-centered outcome study of walking ability and current health status to investigate important health outcomes that impact the quality of life, participation, and activity on adults with cerebral palsy who took part in a gait analysis during childhood at the Center for Gait and Movement Analysis (CGMA). The goal is to see whether their health and walking ability has changed since leaving the Children's Hospital Colorado (CHCO) system and understand if there is a relationship between maintaining proper walking ability and health status. The investigators are including the measure of health outcomes to better understand if a decline in walking ability relates to a decline in health status. The first aim is to study the walking ability of adults with cerebral palsy by comparing their results of a gait analysis to the same results collected when they were children. The second aim is to study the presence of heart disease risk factors by testing each participant's blood levels of lipids, glucose, and insulin. The investigators will also measure each participant's blood pressure. The third aim is to study the relationship(s) between inflammatory markers, neurotrophic factors, and pain and fatigue levels. The investigators will measure inflammatory markers through a blood test and pain and fatigue levels through standardized assessments. The fourth aim is to study each participant's mental health. The investigators will measure this through standardized psychological assessments. The fifth aim is to study each participant's self-perceived health and quality of life as well as employment status. The investigators will measure these levels also through standardized assessments.
Social anhedonia is a hallmark symptom of schizophrenia. Discrepancies in anticipated versus consummatory pleasure for non-social stimuli are well-documented. Thus, a similar emotional paradox may underlie social anhedonia. If so, our understanding of social anhedonia-including how to treat it in schizophrenia-could be enhanced. This project used a 5-day experience sampling method (ESM) to measure discrepancies between anticipated and consummatory pleasure for real-world social activities in people with schizophrenia and healthy controls (n = 30/group). ESM results were compared to laboratory assessments of negative symptoms and neurocognition. The schizophrenia group exhibited similar levels of anticipated and consummatory social pleasure as controls throughout daily life, and both groups were accurate in their short-term predictions of pleasure. Clinical interviews revealed those with schizophrenia showed significant deficits in long-term social pleasure prediction (i.e., a 1-week timeframe). Thus, people with schizophrenia may exhibit differences in ability to predict pleasure in the short-term versus the long-term. Negative symptoms and neurocognition were related to anticipated, but not consummatory, social pleasure, suggesting anhedonia is driven by deficits in thinking about pleasure, rather than inability to experience pleasure. Clinical implications include focusing on building upon short-term ability to predict pleasure in therapy to increase social motivation in schizophrenia.
We adopt Rapley's (2008) concept of distributed decision making to explore the role of the body in people's decisions to seek medical care. We conducted in-depth interviews with patients diagnosed with atrial fibrillation (AF) who were taking long-term anticoagulants to prevent stroke. We interviewed seventeen patients recruited from English anticoagulant clinics using the biographic-narrative-interpretive method, and conducted thematic, structural and metaphorical analyses. This pluralistic analysis focused on how distributed decision-making was enacted through a range of socio-material, relational and embodied practices. Participants told how they experienced AF-related sensations that fluctuated in intensity and form. Some had no symptoms at all; others experienced sudden incapacitation - these experiences shaped different journeys towards seeking medical help. We draw on work by Mol (2002) to show how the body was differently observed, experienced and done across contexts as the narratives unfolded. We show that as part of a relational assemblage, involving social, material and technological actors over time, a new body-in-need-of-help was enacted and medical help sought. This body-in-need-of-help was collectively discussed, interpreted and experienced through distribution of body parts, fluids and technological representations to shape decisions. RAPLEY T., 2008. Distributed decision making: the anatomy of decisions-in-action. Sociology of Health & Illness, 30, 429-444. MOL A., 2002. The body multiple: ontology in medical practice. Duke University Press: Durham.
The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
The program will provide a seven-month program comprising two primary therapies: a three-month intensive behavioral therapy (IBT) and a four-month maintenance behavioral therapy (MBT). The three-month IBT will involve 12-week visits and exercise sessions. The program will encompass in-person (clinic/ health center) and online (telehealth) 12-weekly visits. The 60-minute consultations and booster sessions will be provided by a qualified multidisciplinary team (obesity nurse, psychologist, nutritionist, and physiotherapist), each consulting in their expertise. In collaboration with the physical education and sports science department at Sultan Qaboos University, mothers in the intervention group will be provided exercise sessions based on their individual metabolic and physiological parameters. The maintenance behavioral therapy will start one month after the end of the IBT and will involve four monthly support meetings on a group level.
OBJECTIVE: To develop and validate a predictive model for sarcopenia.
METHODS: A total of 240 subjects who visited our hospital between August 2021 and May 2023 were randomly divided by time of entry into a training set containing 2/3 of patients and a validation set containing 1/3 of patients. The muscle thickness (MT), echo intensity (EI), and shear wave velocity (SWV) of the medial gastrocnemius muscle were measured. Indicators that were meaningful in the univariate analysis in the training set were included in a binary logistic regression to derive a regression model, and the model was evaluated using a consistency index, calibration plot, and clinical validity curve. Diagnostic efficacy and clinical applicability were compared between the model and unifactorial indicators.
RESULTS: Four meaningful variables, age, body mass index (BMI), MT, and SWV, were screened into the predictive model. The model was Logit Y = 21.292 + 0.065 × Age - 0.411 × BMI - 0.524 × MT - 3.072 × SWV. The model was well differentiated with an internally validated C-index of 0.924 and an external validation C-index of 0.914. The calibration plot predicted probabilities against actual probabilities showed excellent agreement. The specificity, sensitivity, and Youden's index of the model were 73.80%, 97.40%, and 71.20%, respectively, when using the diagnostic cut-off value of >0.279 for sarcopenia. The logistic model had higher diagnostic efficacy (p < 0.001) and higher net clinical benefit (p < 0.001) over the same threshold range compared to indicators.
CONCLUSION: The logistic model of sarcopenia has been justified to have good discriminatory, calibrated, and clinical validity, and has higher diagnostic value than indicators.
A hypoxic microenvironment is a characteristic of many solid tumors including pancreatic cancer. The presence of hypoxia in solid tumors is associated with a more malignant phenotype and resistance to chemotherapy. The hypoxia-activated prodrug, TH-302, is designed to selectively physiologically target the hypoxic microenvironment. There is an absence of therapeutic options for subjects with metastatic pancreatic cancer. Gemcitabine provides clinical benefit as a single agent, but median survival is about 6 months. Combining gemcitabine with TH-302 may enable the targeting of both the normoxic and hypoxic regions of pancreatic cancer.
Biodegradable polymeric compositions are provided, wherein biodegradable polyphosphazenes are combined with at least one other polymer, either in the form of a blend, a semi-interpenetrating network (semi-IPN), or an interpenetrating network IPN. The side groups and composition of the polyphosphazenes are used to determine the properties of the compositions, for example, the rate and extent of degradation, and mechanical properties. These are useful in biomedical applications, including controlled drug delivery and tissue regeneration, and environmental applications. In the most preferred embodiment, as demonstrated by the examples, the polyphosphazenes contain hydrophobic side groups, such as p-methylphenoxy and other aromatic groups, and groups which impart hydrolytic instability, such as amino acid alkyl esters, and degrade by surface erosion. A preferred example is ethyl glycinato-substituted polyphosphazene (PPHOS) with p-methylphenoxy as co-substituent. These are blended with other polymers, such as PLGA, which have desirable mechanical properties but which degrade by bulk erosion, so that the blend degrades by surface erosion. For the biomedical applications, FDA approved polymers, such as polymers of lactic and glycolic acids and their copolymers, are preferred. Methods for making these compositions also are provided.
A method of determining a quality of care provided by a healthcare provider to individuals in a population is provided. A data processing apparatus that has one or more processors is disclosed. Data representing biomarkers for individuals in a population is received. Baseline and present risks are determined. Risk reduction values are determined. Based on the current risk reduction, a quality score is determined. A scale is created, and the quality score is mapped to the scale. The global quality score of the disclosure provides numerous benefits over past performance measures.
Patients with acute coronary artery disease (CAD) exhibit reduced global and regional strain and strain rate (S/SR). However, knowledge about segmental S/SR in stable CAD patients is still limited. This study aimed to investigate whether resting segmental S/SR measurements differ in patients with chronic chest pain who have normal coronary arteries or stenotic coronary arteries, and to compare these measurements to those in patients with revascularized myocardial infarction (MI). We prospectively enrolled 510 patients with chronic chest pain referred for coronary computed tomography angiography (CCTA) and 102 patients revascularized after MI. All participants underwent transthoracic echocardiography featuring S/SR analysis. In addition to the patients with MI, patients with suspected CAD based on CCTA findings subsequently underwent invasive coronary angiography (CAG). We assessed global longitudinal strain (GLS) and averaged segmental peak longitudinal strain during systole (PLS), peak systolic strain rate (SRs), peak early diastolic strain rate (SRe), and post systolic shortening (PSS). We also determined functionally reduced segment percentages using differing S/SR cut-off values. There were significant disparities in all average segmental S/SR metrics between the No-CAD and MI groups. SRe was the only S/SR metric that differed significantly between the No-CAD and PCI groups. Differences in SRe, PLS and GLS measurements were observed between the No-CAD and CABG groups. The proportion of diminished segmental S/SR mirrored these findings. For the percentage of pathological segments with varying cut-off values, segmental SRe below 1.5 s- 1 displayed the most marked difference among the four groups (p < 0.001). Revascularized MI patients or those referred to CABG present with diminished segmental S/SR values. However, among patients with chronic chest pain, only segmental SRe discerns subtle disparities between the No-CAD and the PCI group. The diagnostic accuracy of SRe warrants further exploration in subsequent studies.
The present invention provides a peptide that promotes insulin secretion, and a use for said peptide. A search for insulin secretion promoting factors present in a culture supernatant of brown adipocytes (BA-SUP) derived from human pluripotent stem cells led to the identification of a bioactive peptide that promotes insulin secretion. Through the development of a peptide that imitates said peptide, it was discovered that a short-chain linear peptide capable of forming an α-helix structure exhibits strong insulin secretion promoting activity. Moreover, it was discovered that by heat-treating said peptide under acidic conditions or freeze-drying the peptide after dissolving in a buffer solution, the peptide becomes an active form having an increased insulin secretion promoting effect. Said peptide exhibited an effect of promoting insulin secretion using pancreatic beta cells, and of reducing the blood sugar level in vivo. The peptide group according to the present invention is expected to be applicable to the development of a therapeutic medication for glucose metabolism disorders.
Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
The system has digital multimedia documents processing computer (1) that is connected to a personal digital assistant through a wireless network e.g. Bluetooth (RTM). The digital assistant includes a graphic interface management application to generate commands that are transmitted by a transport layer to the computer. The computer triggers the execution of actions interpreted from the command by a multimedia processing application. The digital multimedia documents processing computer and the personal digital assistant are realized in open system interconnection (OSI) model. The command is generated by the personal digital assistant in a protocol e.g. user datagram protocol (UDP), common to the digital documents processing computer and the digital assistant. The multimedia document includes images, sounds or videos. The actions executed by the processing computer includes the action of reception and transmission of multimedia documents, actions of local storing in a data base, and the actions of presentation of the multimedia documents. An independent claim is also included for a multimedia equipment control process.
A medical information management system records patient's medical information onto an optical card (5) for management purposes. For each patient, any suitable information selected from among character, image and sound information is recorded onto the optical card (5) as medical information corresponding to the patient's morbid state. A read section (3, 4) optically reads out the medical information written on the optical card. A display section (23) visually presents the character and image information contained in the medical information that is read out by the read section. A reproduction section (13) audibly reproduces the sound information contained in the medical information that is also read out by the read section. Thus, a doctor can easily acquire or diagnose the patient's morbid state by listening to the patient's characteristic cardiac sounds, cardiac murmurs and breathing sounds, particularly to the cardiac murmurs if the patient has some circulatory disease. By also displaying the sound information as a sound waveform diagram at the same time, more accurate acquisition of the morbid state can be achieved.
The invention provides a preparation method of fenofibrate nano-crystal powder and application of the fenofibrate nano-crystal powder in preparation of oral solid medicaments, and belongs to the field of pharmaceutical preparations. The fenofibrate nano-crystal powder is prepared by adding a hydrophilic auxiliary material and a surface active agent serving as a spray drying supporting agent into a drug-containing nano mixed suspension, and adopting a spray drying method. The mass percent of the spray drying supporting agent to fenofibrate is (1:10) to (10:1). The spray drying supporting agent is preferably a mixture of mannitol and lauryl sodium sulfate, and the ratio of the mannitol to the lauryl sodium sulfate is (15:1) to (5:1). The average particle diameter of the prepared spray-dried powder which is re-dispersed in water is smaller than 1,000 nm. The preparation method can be used for industrial production and has an industrialization production prospect. The spray-dried powder and the pharmaceutically acceptable drug auxiliary material are used for preparing a solid oral preparation, so that the in-vitro dissolution and the in-vivo bioavailability of the fenofibrate can be significantly improved.